Add the AKT inhibitor capivasertib to the list of non-chemo options for hormone-receptor(+) HER2(-) breast cancer refractory to aromatase inhibition with the phase 3 trial CAPItello-291l reporting a significant improvement in progression-free survival when added to fulvestrant even with 70% failing prior CDK4/6-inhibition. | Turner, N Engl J Med 2023
